Physician profile
Kellye Singletary
NPI 1063433324
$1,579.06
in general payments reported to CMS, 2019-2025
14 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $145 · 2021: $357 · 2022: $387 · 2023: $206 · 2024: $79.52 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $280.45 | 2019-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $254.34 | 2019-2024 | Ingrezza |
| Alkermes, INC. | $253.58 | 2019-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $157.86 | 2019-2023 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $124.82 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $123.08 | 2021-2022 | |
| Lundbeck LLC | $73.53 | 2019-2022 | |
| Abbvie INC. | $71.39 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $65.91 | 2020-2021 | |
| Neuronetics, INC. | $58.67 | 2021-2025 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $58.09 | 2021 | |
| Indivior INC. | $32.95 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $12.41 | 2019 | |
| Allergan, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellye Singletary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.